Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

desmethylselegiline

Known as: demethyl-deprenyl-DMD, di-N-propargylamphetamine, N-desmethyl-selegiline 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Nitric oxide (NO), in excess, behaves as a cytotoxic substance mediating the pathological processes that cause neurodegeneration… Expand
2003
2003
Hair and plasma from patients on long-term selegiline medication were analyzed to evaluate the relationships between plasma and… Expand
Highly Cited
2001
Highly Cited
2001
The development of transgenic mouse models of amyotrophic lateral sclerosis (ALS) allows the testing of neuroprotective agents… Expand
Highly Cited
2000
Highly Cited
2000
The paper provides an interdisciplinary evaluation of the etiology, pathogenesis, and experimental treatments of retinitis… Expand
Highly Cited
2000
Highly Cited
2000
We investigated the effects of selegiline and desmethylselegiline on synthesis of neurotrophic factors in cultured mouse… Expand
2000
2000
The goal of this study was to examine the multiple-dose pharmacokinetics of selegiline and its metabolites desmethylselegiline, l… Expand
Highly Cited
1998
Highly Cited
1998
Oxidative stress is thought to play an important role in the pathogenesis of Parkinson's disease (PD). Glutathione (GSH), a major… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Highly Cited
1997
Highly Cited
1997
Abstract: Selegiline [l‐(−)‐deprenyl], a monoamine oxidase B inhibitor, has been used in the treatment of Parkinson's disease as… Expand
Review
1996
Review
1996
The acetylenic selective monoamine oxidase (MAO) type B suicide inhibitor selegiline (previously called L-deprenyl) has proved to… Expand
1993
1993
A sensitive and specific assay for the quantitative determination of amphetamine, methamphetamine and desmethyldeprenyl in human… Expand